The DOI matches its Crossref record; 309 of the 309 references it cites were found in a registry or an index.
HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis
Open accessAbstract
BACKGROUND: Cardiovascular disease (CVD) is the most frequent cause of death in people with early stages of chronic kidney disease (CKD), for whom the absolute risk of cardiovascular events is similar to people who have existing coronary artery disease. This is an update of a review published in 2009, and includes evidence from 27 new studies (25,068 participants) in addition to the 26 studies (20,324 participants) assessed previously; and excludes three previously included studies (107 participants). This updated review includes 50 studies (45,285 participants); of these 38 (37,274 participants) were meta-analysed. OBJECTIVES: To evaluate the benefits (such as reductions in all-cause and cardiovascular mortality, major cardiovascular events, MI and stroke; and slow progression of CKD to end-stage kidney disease (ESKD)) and harms (muscle and liver dysfunction, withdrawal, and cancer) of statins compared with placebo, no treatment, standard care or another statin in adults with CKD who were not on dialysis. SEARCH METHODS: We searched the Cochrane Renal Group's Specialised Register to 5 June 2012 through contact with the Trials' Search Co-ordinator using search terms relevant to this review. SELECTION CRITERIA: Randomised controlled trials (RCTs) and quasi-RCTs that compared the effects of statins with placebo, no treatment, standard care, or other statins, on mortality, cardiovascular events, kidney function, toxicity, and lipid levels in adults with CKD not on dialysis were the focus of our literature searches. DATA COLLECTION AND ANALYSIS: Two or more authors independently extracted data and assessed study risk of bias. Treatment effects were expressed as mean difference (MD) for continuous outcomes (lipids, creatinine clearance and proteinuria) and risk ratio (RR) for dichotomous outcomes (major cardiovascular events, all-cause mortality, cardiovascular mortality, fatal or non-fatal myocardial infarction (MI), fatal or non-fatal stroke, ESKD, elevated liver enzymes, rhabdomyolysis, cancer and withdrawal rates) with 95% confidence intervals (CI). MAIN RESULTS: We included 50 studies (45,285 participants): 47 studies (39,820 participants) compared statins with placebo or no treatment and three studies (5547 participants) compared two different statin regimens in adults with CKD who were not yet on dialysis. We were able to meta-analyse 38 studies (37,274 participants).The risk of bias in the included studies was high. Seven studies comparing statins with placebo or no treatment had lower risk of bias overall; and were conducted according to published protocols, outcomes were adjudicated by a committee, specified outcomes were reported, and analyses were conducted using intention-to-treat methods. In placebo or no treatment controlled studies, adverse events were reported in 32 studies (68%) and systematically evaluated in 16 studies (34%).Compared with placebo, statin therapy consistently prevented major cardiovascular events (13 studies, 36,033 participants; RR 0.72, 95% CI 0.66 to 0.79), all-cause mortality (10 studies, 28,276 participants; RR 0.79, 95% CI 0.69 to 0.91), cardiovascular death (7 studies, 19,059 participants; RR 0.77, 95% CI 0.69 to 0.87) and MI (8 studies, 9018 participants; RR 0.55, 95% CI 0.42 to 0.72). Statins had uncertain effects on stroke (5 studies, 8658 participants; RR 0.62, 95% CI 0.35 to 1.12).Potential harms from statin therapy were limited by lack of systematic reporting and were uncertain in analyses that had few events: elevated creatine kinase (7 studies, 4514 participants; RR 0.84, 95% CI 0.20 to 3.48), liver function abnormalities (7 studies, RR 0.76, 95% CI 0.39 to 1.50), withdrawal due to adverse events (13 studies, 4219 participants; RR 1.16, 95% CI 0.84 to 1.60), and cancer (2 studies, 5581 participants; RR 1.03, 95% CI 0.82 to 130).Statins had uncertain effects on progression of CKD. Data for relative effects of intensive cholesterol lowering in people with early stages of kidney disease were sparse. Statins clearly reduced risks of death, major cardiovascular events, and MI in people with CKD who did not have CVD at baseline (primary prevention). AUTHORS' CONCLUSIONS: Statins consistently lower death and major cardiovascular events by 20% in people with CKD not requiring dialysis. Statin-related effects on stroke and kidney function were found to be uncertain and adverse effects of treatment are incompletely understood. Statins have an important role in primary prevention of cardiovascular events and mortality in people who have CKD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
GRADE: an emerging consensus on rating quality of evidence and strength of recommendations
Guyatt, G. H., Oxman, A. D., Vist, G. E., Kunz, R., Falck-Ytter, Y., Alonso-Coello, P., & Schünemann, H. J. (2008) · BMJ · doi:10.1136/bmj.39489.470347.ad · Cited by 23,305
Duval, S., & Tweedie, R. (2000) · Biometrics · doi:10.1111/j.0006-341x.2000.00455.x · Cited by 14,099
Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization
Go, A. S., Chertow, G. M., Fan, D., McCulloch, C. E., & Hsu, C.-Y. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041031 · Cited by 11,369
OLSSON, A. G., McMurray, J. J. V., Thorgeirsson, G., Spaulding, C. M., Slattery, J., Pyörälà, K., Færgeman, O., Wright, R. S., Berg, K. M., Wilhelmsen, L., et al. (1994) · The Lancet · Cited by 8,467
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437738.63853.7a · Cited by 7,081
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0807646 · Cited by 6,674
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.23.2981 · Cited by 5,664
(1998) · New England Journal of Medicine · doi:10.1056/nejm199811053391902 · Cited by 5,261
Downs, J. R., Clearfield, M., Weis, S., Whitney, E., Shapiro, D. R., Beere, P. A., Langendorfer, A., Stein, E. A., Kruyer, W., Gotto, Jr., et al. (1998) · JAMA · doi:10.1001/jama.279.20.1615 · Cited by 5,236
Prevalence of Chronic Kidney Disease in the United States
Coresh, J., Selvin, E., Stevens, L. A., Manzi, J., Kusek, J. W., Eggers, P., Van Lente, F., & Levey, A. S. (2007) · JAMA · doi:10.1001/jama.298.17.2038 · Cited by 4,895
Levey, A. S., Coresh, J., Balk, E., Kausz, A. T., Levin, A., Steffes, M. W., Hogg, R. J., Perrone, R. D., Lau, J., & Eknoyan, G. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-139-2-200307150-00013 · Cited by 4,615
Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes
Gæde, P., Vedel, P., Larsen, N., Jensen, G. V. H., Parving, H.-H., & Pedersen, O. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021778 · Cited by 4,378
Clinical epidemiology of cardiovascular disease in chronic renal disease
Foley, R., Parfrey, P., & Sarnak, M. (1998) · American Journal of Kidney Diseases · doi:10.1053/ajkd.1998.v32.pm9820470 · Cited by 3,958
Sever, P. S., Dahlöf, B., Poulter, N. R., Wedel, H., Beevers, G., Caulfield, M., Collins, R., Kjeldsen, S. E., Kristinsson, A., McInnes, G. T., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12948-0 · Cited by 3,782
Colhoun, H. M., Betteridge, D. J., Durrington, P. N., Hitman, G. A., W Neil, H. A., Livingstone, S. J., Thomason, M. J., Mackness, M. I., Charlton-Menys, V., & Fuller, J. H. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16895-5 · Cited by 3,755
SCANDINAVIANSIMVASTATINSURVIVAL (1994) · The Lancet · doi:10.1016/s0140-6736(94)90566-5 · Cited by 3,645
Rosuvastatin to Prevent Vascular Events in Men and Women With Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2009) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000344393.60303.0a · Cited by 3,641
Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease
LaRosa, J. C., Grundy, S. M., Waters, D. D., Shear, C., Barter, P., Fruchart, J.-C., Gotto, A. M., Greten, H., Kastelein, J. J. P., Shepherd, J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050461 · Cited by 3,489
Effect of a multifactorial intervention on mortality in type 2 diabetes
Gæde, P., Lund-Andersen, H., Parving, H.-H., & Pedersen, O. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706245 · Cited by 3,465
PEDERSEN, T. R. (2004) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2004.08.027 · Cited by 3,106
Baigent, C., Landray, M. J., Reith, C., Emberson, J., Wheeler, D. C., Tomson, C., Wanner, C., Krane, V., Cass, A., Craig, J., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60739-3 · Cited by 2,479
Self-citationA modified test for small‐study effects in meta‐analyses of controlled trials with binary endpoints
Harbord, R. M., Egger, M., & Sterne, J. A. C. (2006) · Statistics in Medicine · doi:10.1002/sim.2380 · Cited by 2,267
Rosuvastatin and Cardiovascular Events in Patients Undergoing Hemodialysis
Fellström, B. C., Jardine, A. G., Schmieder, R. E., Holdaas, H., Bannister, K., Beutler, J., Chae, D.-W., Chevaile, A., Cobbe, S. M., Grönhagen-Riska, C., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810177 · Cited by 2,036
Relation between Renal Dysfunction and Cardiovascular Outcomes after Myocardial Infarction
Anavekar, N. S., McMurray, J. J. V., Velazquez, E. J., Solomon, S. D., Kober, L., Rouleau, J.-L., White, H. D., Nordlander, R., Maggioni, A., Dickstein, K., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041365 · Cited by 1,917
Pyörälä, K., Pedersen, T. R., Kjekshus, J., Faergeman, O., Olsson, A. G., Thorgeirsson, G., & The Scandinavian Simvastatin Survival Study (4S) Group (1997) · Diabetes Care · doi:10.2337/diacare.20.4.614 · Cited by 1,623
HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events
Barter, P., Gotto, A. M., LaRosa, J. C., Maroni, J., Szarek, M., Grundy, S. M., Kastelein, J. J. P., Bittner, V., & Fruchart, J.-C. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa064278 · Cited by 1,610
Pedersen, T. R. (2005) · JAMA · doi:10.1001/jama.294.19.2437 · Cited by 1,548
The contribution of chronic kidney disease to the global burden of major noncommunicable diseases
Couser, W. G., Remuzzi, G., Mendis, S., & Tonelli, M. (2011) · Kidney International · doi:10.1038/ki.2011.368 · Cited by 1,513
Sattar, N., Gaw, A., Scherbakova, O., Ford, I., O’Reilly, D. S. J., Haffner, S. M., Isles, C., Macfarlane, P. W., Packard, C. J., Cobbe, S. M., et al. (2003) · Circulation · doi:10.1161/01.cir.0000080897.52664.94 · Cited by 1,506
The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group (2000) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.283.15.1967 · Cited by 1,499
The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.23.2998 · Cited by 1,331
Gæde, P., Vedel, P., Parving, H.-H., & Pedersen, O. (1999) · The Lancet · doi:10.1016/s0140-6736(98)07368-1 · Cited by 981
Cushman, W. C., Ford, C. E., Cutler, J. A., Margolis, K. L., Davis, B. R., Grimm, R. H., Black, H. R., Hamilton, B. P., Holland, J., Nwachuku, C., et al. (2002) · The Journal of Clinical Hypertension · doi:10.1111/j.1524-6175.2002.02045.x · Cited by 979
Foley, R. N., Murray, A. M., Li, S., Herzog, C. A., McBean, A. M., Eggers, P. W., & Collins, A. J. (2005) · Journal of the American Society of Nephrology · doi:10.1681/asn.2004030203 · Cited by 972
Nakamura, H., Arakawa, K., Itakura, H., Kitabatake, A., Goto, Y., Toyota, T., Nakaya, N., Nishimoto, S., Muranaka, M., Yamamoto, A., et al. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69472-5 · Cited by 941
Manjunath, G., Tighiouart, H., Ibrahim, H., MacLeod, B., Salem, D. N., Griffith, J. L., Coresh, J., Levey, A. S., & Sarnak, M. J. (2003) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(02)02663-3 · Cited by 920
Boutron, I. (2010) · JAMA · doi:10.1001/jama.2010.651 · Cited by 842
Wallace, A. M., McMahon, A. D., Packard, C. J., Kelly, A., Shepherd, J., Gaw, A., & Sattar, N. (2001) · Circulation · doi:10.1161/hc5001.101061 · Cited by 825
Lipoprotein-Associated Phospholipase A2as an Independent Predictor of Coronary Heart Disease
Packard, C. J., O'Reilly, D. S. J., Caslake, M. J., McMahon, A. D., Ford, I., Cooney, J., Macphee, C. H., Suckling, K. E., Krishna, M., Wilkinson, F. E., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200010193431603 · Cited by 823
(1998) · Circulation · doi:10.1161/01.cir.97.15.1440 · Cited by 796
A Randomized Trial of Rosuvastatin in the Prevention of Venous Thromboembolism
Glynn, R. J., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900241 · Cited by 752
Brouilette, S. W., Moore, J. S., McMahon, A. D., Thompson, J. R., Ford, I., Shepherd, J., Packard, C. J., & Samani, N. J. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60071-3 · Cited by 745
Shlipak, M. G., Fried, L. F., Cushman, M., Manolio, T. A., Peterson, D., Stehman-Breen, C., Bleyer, A., Newman, A., Siscovick, D., & Psaty, B. (2005) · JAMA · doi:10.1001/jama.293.14.1737 · Cited by 735
Freeman, D. J., Norrie, J., Caslake, M. J., Gaw, A., Ford, I., Lowe, G. D. O., O’Reilly, D. S. J., Packard, C. J., Sattar, N., & for the West of Scotland Coronary Prevention Study Group (2002) · Diabetes · doi:10.2337/diabetes.51.5.1596 · Cited by 728
Resistin Promotes Endothelial Cell Activation: Further Evidence of Adipokine-Endothelial Interaction
Verma, S., Li, S.-H., Wang, C.-H., Fedak, P. W. M., Li, R.-K., Weisel, R. D., & Mickle, D. A. G. (2003) · Circulation · doi:10.1161/01.cir.0000084503.91330.49 · Cited by 670
Pedersen, T. R., Olsson, A. G., Færgeman, O., Kjekshus, J., Wedel, H., Berg, K., Wilhelmsen, L., Haghfelt, T., Thorgeirsson, G., Pyörälä, K., et al. (1998) · Circulation · doi:10.1161/01.cir.97.15.1453 · Cited by 621
Davis, B. (1996) · American Journal of Hypertension · doi:10.1016/0895-7061(96)00037-4 · Cited by 595
Grassmann, A., Gioberge, S., Moeller, S., & Brown, G. (2005) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfi159 · Cited by 566
Mild renal insufficiency is associated with increased cardiovascular mortality: The Hoorn Study
Henry, R. M. A., Kostense, P. J., Bos, G., Dekker, J. M., Nijpels, G., Heine, R. J., Bouter, L. M., & Stehouwer, C. D. A. (2002) · Kidney International · doi:10.1046/j.1523-1755.2002.00571.x · Cited by 552
Shepherd, J., Barter, P., Carmena, R., Deedwania, P., Fruchart, J.-C., Haffner, S., Hsia, J., Breazna, A., LaRosa, J., Grundy, S., et al. (2006) · Diabetes Care · doi:10.2337/dc05-2465 · Cited by 525
Sever, P. S., Dahl??f, B., Poulter, N. R., Wedel, H., Beevers, G., Caulfield, M., Collins, R., Kjeldsen, S. E., Kristinsson, A., McInnes, G. T., et al. (2004) · Drugs · doi:10.2165/00003495-200464002-00005 · Cited by 524
Effects of Fosinopril and Pravastatin on Cardiovascular Events in Subjects With Microalbuminuria
Asselbergs, F. W., Diercks, G. F. H., Hillege, H. L., van Boven, A. J., Janssen, W. M. T., Voors, A. A., de Zeeuw, D., de Jong, P. E., van Veldhuisen, D. J., & van Gilst, W. H. (2004) · Circulation · doi:10.1161/01.cir.0000146378.65439.7a · Cited by 523
Miettinen, T. A., Pyörälä, K., Olsson, A. G., Musliner, T. A., Cook, T. J., Faergeman, O., Berg, K., Pedersen, T., Kjekshus, J., & Group, F. T. S. S. S. (1997) · Circulation · doi:10.1161/01.cir.96.12.4211 · Cited by 508
Muntner, P., He, J., Astor, B. C., Folsom, A. R., & Coresh, J. (2005) · Journal of the American Society of Nephrology · doi:10.1681/asn.2004080656 · Cited by 493
Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment
Kastelein, J. J. P., van der Steeg, W. A., Holme, I., Gaffney, M., Cater, N. B., Barter, P., Deedwania, P., Olsson, A. G., Boekholdt, S. M., Demicco, D. A., et al. (2008) · Circulation · doi:10.1161/circulationaha.107.713438 · Cited by 478
Pedersen, T. R., Kjekshus, J., Pyörälä, K., Olsson, A. G., Cook, T. J., Musliner, T. A., Tobert, J. A., & Haghfelt, T. (1998) · The American Journal of Cardiology · doi:10.1016/s0002-9149(97)00904-1 · Cited by 466
Cholesterol and the risk of renal dysfunction in apparently healthy men
Schaeffner, E. S., Kurth, T., Curhan, G. C., Glynn, R. J., Rexrode, K. M., Baigent, C., Buring, J. E., & Gaziano, J. M. (2003) · Journal of the American Society of Nephrology · doi:10.1681/asn.v1482084 · Cited by 442
Haffner, S. M. (1999) · Archives of Internal Medicine · doi:10.1001/archinte.159.22.2661 · Cited by 441
Long-term follow-up of the West of Scotland Coronary Prevention Study
Ford, I., Murray, H., Packard, C. J., Shepherd, J., Macfarlane, P. W., & Cobbe, S. M. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065994 · Cited by 416
Ballantyne, C. M., Olsson, A. G., Cook, T. J., Mercuri, M. F., Pedersen, T. R., & Kjekshus, J. (2001) · Circulation · doi:10.1161/hc5001.100624 · Cited by 416
Pleiotropic Effects of Statins: Benefit Beyond Cholesterol Reduction?
Robinson, J. G., Smith, B., Maheshwari, N., & Schrott, H. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.05.085 · Cited by 407
Strippoli, G. F. M., Navaneethan, S. D., Johnson, D. W., Perkovic, V., Pellegrini, F., Nicolucci, A., & Craig, J. C. (2008) · BMJ · doi:10.1136/bmj.39472.580984.ae · Cited by 402
Self-citationReduction in Cardiovascular Events With Atorvastatin in 2,532 Patients With Type 2 Diabetes
Sever, P. S., Poulter, N. R., Dahlöf, B., Wedel, H., Collins, R., Beevers, G., Caulfield, M., Kjeldsen, S. E., Kristinsson, A., McInnes, G. T., et al. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1151 · Cited by 390
Sacks, F. M., Tonkin, A. M., Shepherd, J., Braunwald, E., Cobbe, S., Hawkins, C. M., Keech, A., Packard, C., Simes, J., Byington, R., et al. (2000) · Circulation · doi:10.1161/01.cir.102.16.1893 · Cited by 388
Deedwania, P., Barter, P., Carmena, R., Fruchart, J.-C., Grundy, S. M., Haffner, S., Kastelein, J. J., LaRosa, J. C., Schachner, H., Shepherd, J., et al. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69292-1 · Cited by 387
Johannesson, M., Jönsson, B., Kjekshus, J., Olsson, A. G., Pedersen, T. R., & Wedel, H. (1997) · New England Journal of Medicine · doi:10.1056/nejm199701303360503 · Cited by 387
Effect of Pravastatin on Cardiovascular Events in People With Chronic Kidney Disease
Tonelli, M., Isles, C., Curhan, G. C., Tonkin, A., Pfeffer, M. A., Shepherd, J., Sacks, F. M., Furberg, C., Cobbe, S. M., Simes, J., et al. (2004) · Circulation · doi:10.1161/01.cir.0000143892.84582.60 · Cited by 381
Sattar, N., Scherbakova, O., Ford, I., O’Reilly, D. S. J., Stanley, A., Forrest, E., MacFarlane, P. W., Packard, C. J., Cobbe, S. M., & Shepherd, J. (2004) · Diabetes · doi:10.2337/diabetes.53.11.2855 · Cited by 375
Biomarkers of inflammation and progression of chronickidney disease
Tonelli, M., Sacks, F., Pfeffer, M., Jhangri, G. S., & Curhan, G. (2005) · Kidney International · doi:10.1111/j.1523-1755.2005.00398.x · Cited by 362
Rahman, M. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.8.936 · Cited by 340
Pravastatin Therapy and the Risk of Stroke
White, H. D., Simes, R. J., Anderson, N. E., Hankey, G. J., Watson, J. D. G., Hunt, D., Colquhoun, D. M., Glasziou, P., MacMahon, S., Kirby, A. C., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200008033430502 · Cited by 338
Bianchi, S., Bigazzi, R., Caiazza, A., & Campese, V. M. (2003) · American Journal of Kidney Diseases · doi:10.1053/ajkd.2003.50140 · Cited by 332
Strandberg, T. E., Pyörälä, K., Cook, T. J., Wilhelmsen, L., Faergeman, O., Thorgeirsson, G., Pedersen, T. R., & Kjekshus, J. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16936-5 · Cited by 331
Weiner, D. E., Tabatabai, S., Tighiouart, H., Elsayed, E., Bansal, N., Griffith, J., Salem, D. N., Levey, A. S., & Sarnak, M. J. (2006) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2006.05.021 · Cited by 325
Study of Heart and Renal Protection (SHARP)
Baigent, C., & Landry, M. (2003) · Kidney International · doi:10.1046/j.1523-1755.63.s84.4.x · Cited by 320
SHARP Collaborative Group (2010) · American Heart Journal · doi:10.1016/j.ahj.2010.08.012 · Cited by 319
Tonelli, M., Moyé, L., Sacks, F. M., Cole, T., & Curhan, G. C. (2003) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000068461.45784.2f · Cited by 306
Shepherd, J., Kastelein, J. J. P., Bittner, V., Deedwania, P., Breazna, A., Dobson, S., Wilson, D. J., Zuckerman, A., & Wenger, N. K. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.11.072 · Cited by 302
Kasiske, B. L., O'Donnell, M. P., Garvis, W. J., & Keane, W. F. (1988) · Circulation Research · doi:10.1161/01.res.62.2.367 · Cited by 291
Pedersen, T. R. (1996) · Archives of Internal Medicine · doi:10.1001/archinte.156.18.2085 · Cited by 286
Koren, M. J., & Hunninghake, D. B. (2004) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2004.07.053 · Cited by 280
Tonelli, M., Moy, L., Sacks, F. M., Kiberd, B., Curhan, G., & for the Cholesterol and Recurrent Events (CARE) Trial Investigators (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-138-2-200301210-00010 · Cited by 278
Reduction of Stroke Events With Pravastatin: The Prospective Pravastatin Pooling (PPP) Project
Byington, R. P., Davis, B. R., Plehn, J. F., White, H. D., Baker, J., Cobbe, S. M., & Shepherd, J. (2001) · Circulation · doi:10.1161/01.cir.103.3.387 · Cited by 276
Di Angelantonio, E., Chowdhury, R., Sarwar, N., Aspelund, T., Danesh, J., & Gudnason, V. (2010) · BMJ · doi:10.1136/bmj.c4986 · Cited by 275
Shepherd, J., Kastelein, J. J. P., Bittner, V., Deedwania, P., Breazna, A., Dobson, S., Wilson, D. J., Zuckerman, A., & Wenger, N. K. (2007) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.04371206 · Cited by 275
Pedersen, T. R., Wilhelmsen, L., Færgeman, O., Strandberg, T. E., Thorgeirsson, G., Troedsson, L., Kristianson, J., Berg, K., Cook, T. J., Haghfelt, T., et al. (2000) · The American Journal of Cardiology · doi:10.1016/s0002-9149(00)00910-3 · Cited by 274
Barzilay, J. I. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.20.2191 · Cited by 265
Miettinen, T. A., Gylling, H., Strandberg, T., & Sarna, S. (1998) · BMJ · doi:10.1136/bmj.316.7138.1127 · Cited by 257
Colhoun, H. M., Betteridge, D. J., Durrington, P. N., Hitman, G. A., Neil, H. A. W., Livingstone, S. J., Charlton-Menys, V., DeMicco, D. A., & Fuller, J. H. (2009) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2009.03.022 · Cited by 255
Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S)
Scandinavian Simvastation Survival Study Group (1995) · The Lancet · doi:10.1016/s0140-6736(95)90926-5 · Cited by 255
Pfeffer, M. A., Keech, A., Sacks, F. M., Cobbe, S. M., Tonkin, A., Byington, R. P., Davis, B. R., Friedman, C. P., & Braunwald, E. (2002) · Circulation · doi:10.1161/01.cir.0000017634.00171.24 · Cited by 241
Gerdes, L. U., Gerdes, C., Kervinen, K., Savolainen, M., Klausen, I. C., Hansen, P. S., Kesäniemi, Y. A., & Færgeman, O. (2000) · Circulation · doi:10.1161/01.cir.101.12.1366 · Cited by 236
Rahman, M., Pressel, S., Davis, B. R., Nwachuku, C., Wright, J. T., Whelton, P. K., Barzilay, J., Batuman, V., Eckfeldt, J. H., Farber, M. A., et al. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-144-3-200602070-00005 · Cited by 227
Tonelli, M., Wanner, C., & for the Kidney Disease: Improving Global Outcomes Lipid Guideline Development Work Group Members* (2014) · Annals of Internal Medicine · doi:10.7326/m13-2453 · Cited by 226
Ridker, P. M., MacFadyen, J., Cressman, M., & Glynn, R. J. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.01.020 · Cited by 220
Reid, I. R., Hague, W., Emberson, J., Baker, J., Tonkin, A., Hunt, D., MacMahon, S., & Sharpe, N. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04042-3 · Cited by 217
Baigent, C., Landray, M., Leaper, C., Altmann, P., Armitage, J., Baxter, A., Cairns, H. S., Collins, R., Foley, R. N., Frighi, V., et al. (2005) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2004.11.015 · Cited by 210
Howard, W. J. (2008) · Yearbook of Endocrinology · doi:10.1016/s0084-3741(08)79115-7 · Cited by 209
Rumley, A., Norrie, J., Ford, I., Shepherd, J., Cobbe, S., Macfarlane, P., Packard, C., Lowe, G., & The West of Scotland Coronary Prevention Study Group (2000) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1614066 · Cited by 208
Caro, J., Klittich, W., McGuire, A., Ford, I., Norrie, J., Pettitt, D., McMurray, J., & Shepherd, J. (1997) · BMJ · doi:10.1136/bmj.315.7122.1577 · Cited by 203
Waters, D. D., Guyton, J. R., Herrington, D. M., McGowan, M. P., Wenger, N. K., & Shear, C. (2004) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2003.09.031 · Cited by 201
Pedersen, T. R., Kjekshus, J., Berg, K., Olsson, A. G., Wilhelmsen, L., Wedel, H., Pyörälä, K., Miettinen, T., Haghfelt, T., Færgeman, O., et al. (1996) · Circulation · doi:10.1161/01.cir.93.10.1796 · Cited by 197
Effect of Pravastatin on Rate of Kidney Function Loss in People With or at Risk for Coronary Disease
Tonelli, M., Isles, C., Craven, T., Tonkin, A., Pfeffer, M. A., Shepherd, J., Sacks, F. M., Furberg, C., Cobbe, S. M., Simes, J., et al. (2005) · Circulation · doi:10.1161/circulationaha.104.517565 · Cited by 197
Cholesterol-lowering therapy may retard the progression of diabetic nephropathy
Lam, K. S. L., Cheng, I. K. P., Janus, E. D., & Pang, R. W. C. (1995) · Diabetologia · doi:10.1007/bf00400731 · Cited by 194
Tonelli, M., Jose, P., Curhan, G., Sacks, F., Braunwald, E., & Pfeffer, M. (2006) · BMJ · doi:10.1136/bmj.38814.566019.2f · Cited by 193
Jonsson, B., Johannesson, M., Kjekshus, J., Olsson, A. G., Pedersen, T. R., Wedel, H., & Scandlnavlan Simvastatin Survival Study Group (1996) · European Heart Journal · doi:10.1093/oxfordjournals.eurheartj.a014994 · Cited by 176
Khush, K. K., Waters, D. D., Bittner, V., Deedwania, P. C., Kastelein, J. J. P., Lewis, S. J., & Wenger, N. K. (2007) · Circulation · doi:10.1161/circulationaha.106.625574 · Cited by 172
Leenen, F. H. H., Nwachuku, C. E., Black, H. R., Cushman, W. C., Davis, B. R., Simpson, L. M., Alderman, M. H., Atlas, S. A., Basile, J. N., Cuyjet, A. B., et al. (2006) · Hypertension · doi:10.1161/01.hyp.0000231662.77359.de · Cited by 171
Briel, M., Schwartz, G. G., Thompson, P. L., de Lemos, J. A., Blazing, M. A., van Es, G.-A., Kayikçioğlu, M., Arntz, H.-R., den Hartog, F. R., Veeger, N. J. G. M., et al. (2006) · JAMA · doi:10.1001/jama.295.17.2046 · Cited by 170
Pyörälä, K., Ballantyne, C. M., Gumbiner, B., Lee, M. W., Shah, A., Davies, M. J., Mitchel, Y. B., Pedersen, T. R., Kjekshus, J., & for the Scandinavian Simvastatin Survival Study Group (2004) · Diabetes Care · doi:10.2337/diacare.27.7.1735 · Cited by 169
Tonolo, G., Ciccarese, M., Brizzi, P., Puddu, L., Secchi, G., Calvia, P., Atzeni, M. M., Melis, M. G., & Maioli, M. (1997) · Diabetes Care · doi:10.2337/diacare.20.12.1891 · Cited by 168
The Anatomy of a Clinical Trial
Shepherd, J., & Gaw, A. (2002) · Medical Principles and Practice · doi:10.1159/000066408 · Cited by 159
Effect of pravastatin in people with diabetes and chronic kidney disease
Tonelli, M., Keech, A., Shepherd, J., Sacks, F., Tonkin, A., Packard, C., Pfeffer, M., Simes, J., Isles, C., Furberg, C., et al. (2005) · Journal of the American Society of Nephrology · doi:10.1681/asn.2005070779 · Cited by 159
HMG CoA reductase inhibitors (statins) for dialysis patients
Navaneethan, S. D., Nigwekar, S. U., Perkovic, V., Johnson, D. W., Craig, J. C., & Strippoli, G. F. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004289.pub3 · Cited by 158
Self-citationHMG CoA reductase inhibitors (statins) for kidney transplant recipients
Palmer, S. C., Navaneethan, S. D., Craig, J. C., Perkovic, V., Johnson, D. W., Nigwekar, S. U., Hegbrant, J., & Strippoli, G. F. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005019.pub4 · Cited by 156
Self-citationThe role of lipids in renal disease: Future challenges
Keane, W. F. (2000) · Kidney International · doi:10.1046/j.1523-1755.2000.07503.x · Cited by 155
Cost-Effectiveness of Intensified Versus Conventional Multifactorial Intervention in Type 2 Diabetes
Gæde, P., Valentine, W. J., Palmer, A. J., Tucker, D. M. D., Lammert, M., Parving, H., & Pedersen, O. B. (2008) · Diabetes Care · doi:10.2337/dc07-2452 · Cited by 155
LaRosa, J. C., Grundy, S. M., Kastelein, J. J. P., Kostis, J. B., & Greten, H. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2007.03.102 · Cited by 148
HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis
Navaneethan, S. D., Pansini, F., Perkovic, V., Manno, C., Pellegrini, F., Johnson, D. W., Craig, J. C., & Strippoli, G. F. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007784 · Cited by 144
Self-citationDowns, J. R., Clearfield, M., Tyroler, H. A., Whitney, E. J., Kruyer, W., Langendorfer, A., Zagrebelsky, V., Weis, S., Shapiro, D. R., Beere, P. A., et al. (2001) · The American Journal of Cardiology · doi:10.1016/s0002-9149(01)01464-3 · Cited by 138
Berg, K., Dahlén, G. H., Christophersen, B. O., Cook, T. J., KJEKSHUS, J. K., & Pedersen, T. (1997) · Clinical Genetics · doi:10.1111/j.1399-0004.1997.tb04342.x · Cited by 136
Monitoring Cholesterol Levels: Measurement Error or True Change?
Glasziou, P., Irwig, L., Heritier, S. R., Simes, R. J., Tonkin, A. M., & for the LIPID Study Investigators (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-148-9-200805060-00005 · Cited by 132
Sever, P., Chang, C. L., Gupta, A. K., Whitehouse, A., & Poulter, N. R. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr333 · Cited by 131
Analysis of Efficacy and Safety in Patients Aged 65–75 Years at Randomization
Neil, H. A. W., DeMicco, D. A., Luo, D., Betteridge, D. J., Colhoun, H. M., Durrington, P. N., Livingstone, S. J., Fuller, J., Hitman, G. A., & on behalf of the CARDS Study Investigators (2006) · Diabetes Care · doi:10.2337/dc06-0872 · Cited by 131
Thobari, J. A., Asselbergs, F. W., Boersma, C., de Vries, R., Hillege, H. L., van Gilst, W. H., Gansevoort, R. T., de Jong, P. E., den Berg, L. T. W. D. J., & Postma, M. J. (2006) · Clinical Therapeutics · doi:10.1016/j.clinthera.2006.03.012 · Cited by 130
Nanayakkara, P. W. B., Teerlink, T., Stehouwer, C. D. A., Allajar, D., Spijkerman, A. M. W., Schalkwijk, C. G., ter Wee, P. M., & van Guldener, C. (2005) · Kidney International · doi:10.1111/j.1523-1755.2005.00680.x · Cited by 129
Koren, M. J., & Hunninghake, D. B. (2005) · ACC Current Journal Review · doi:10.1016/j.accreview.2004.12.117 · Cited by 129
Ridker, P. M., Fonseca, F. A. H., Genest, J. J., Gotto, A. M., Kastelein, J. J. P., Khurmi, N. S., Köenig, W., Libby, P., Lorenzatti, A. J., Nordestgaard, B. G., et al. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2007.09.072 · Cited by 125
Sacks, F. M., Pfeffer, M. A., Moyé, L. A., Brown, L. E., Hamm, P., Cole, T. G., HAWKINS, C. M., Braunwald, E., & The CARE Investigators (1991) · The American Journal of Cardiology · doi:10.1016/0002-9149(91)90276-q · Cited by 125
(1995) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(95)00530-7 · Cited by 123
USRDS: the United States Renal Data System.
(2003) · PubMed · Cited by 123
Cobbe, S. M. (1997) · The American Journal of Cardiology · doi:10.1016/s0002-9149(96)00863-6 · Cited by 118
Rosuvastatin in Diabetic Hemodialysis Patients
Holdaas, H., Holme, I., Schmieder, R. E., Jardine, A. G., Zannad, F. M., Norby, G. E., & Fellström, B. (2011) · Journal of the American Society of Nephrology · doi:10.1681/asn.2010090987 · Cited by 118
Davis, B. R., Cutler, J. A., Cd, F., Wright, J. T., Farber, M. A., Felicetta, J. V., & Stokes, J. D. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-5_part_1-200209030-00006 · Cited by 116
Nanayakkara, P. W. B., van Guldener, C., ter Wee, P. M., Scheffer, P. G., van Ittersum, F. J., Twisk, J. W. R., Teerlink, T., van Dorp, W., & Stehouwer, C. D. A. (2007) · Archives of Internal Medicine · doi:10.1001/archinte.167.12.1262 · Cited by 116
Focused Atorvastatin Therapy in Managed-Care Patients With Coronary Heart Disease and CKD
Koren, M. J., Davidson, M. H., Wilson, D. J., Fayyad, R. S., Zuckerman, A., & Reed, D. P. (2009) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2008.11.025 · Cited by 115
Wright, J. T. (2008) · Archives of Internal Medicine · doi:10.1001/archinternmed.2007.66 · Cited by 114
Heart Protection Study Collaborative Group (2005) · BMC Medicine · doi:10.1186/1741-7015-3-6 · Cited by 114
HMG CoA reductase inhibitors (statins) for dialysis patients
Palmer, S. C., Navaneethan, S. D., Craig, J. C., Johnson, D. W., Perkovic, V., Nigwekar, S. U., Hegbrant, J., & Strippoli, G. F. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004289.pub5 · Cited by 114
Self-citationEffect of Pravastatin on Proteinuria in Patients With Well-Controlled Hypertension
Lee, T., Su, S.-F., & Tsai, C. (2002) · Hypertension · doi:10.1161/01.hyp.0000022805.11288.7f · Cited by 113
ALLHAT Findings Revisited in the Context of Subsequent Analyses, Other Trials, and Meta-analyses
Wright, J. T., Probstfield, J. L., Cushman, W. C., Pressel, S. L., Cutler, J. A., Davis, B. R., Einhorn, P. T., Rahman, M., Whelton, P. K., Ford, C. E., et al. (2009) · Archives of Internal Medicine · doi:10.1001/archinternmed.2009.60 · Cited by 113
Heart Protection Study Collaborative Group (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.08.052 · Cited by 110
Nakamura, T., Sugaya, T., Kawagoe, Y., Ueda, Y., Osada, S., & Koide, H. (2005) · Diabetes Care · doi:10.2337/diacare.28.11.2728 · Cited by 109
Landray, M., Baigent, C., Leaper, C., Adu, D., Altmann, P., Armitage, J., Ball, S. T., Baxter, A., Blackwell, L. S., Cairns, H., et al. (2006) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2005.11.018 · Cited by 107
Sever, P., Poulter, N. R., Dahlöf, B., Wedel, H., Beevers, G., Caulfield, M. J., Collins, R., Kjeldsen, S. E., Kristinsson, A., McInnes, G. T., et al. (2008) · European Heart Journal · doi:10.1093/eurheartj/ehm583 · Cited by 105
Clearfield, M. B., Downs, J. R., Weis, S. E., Whitney, E. J., Kruyer, W. B., Shapiro, D. R., Stein, E. A., Langendörfer, A., Beere, P. A., & Gotto, A. M. (2001) · Journal of Women s Health & Gender-Based Medicine · doi:10.1089/152460901317193549 · Cited by 104
Mizuno, K., Nakaya, N., Ohashi, Y., Tajima, N., Kushiro, T., Teramoto, T., Uchiyama, S., & Nakamura, H. (2008) · Circulation · doi:10.1161/circulationaha.106.671826 · Cited by 102
Shah, S. J., Waters, D. D., Barter, P. J., Kastelein, J. J. P., Shepherd, J., WENGER, N. K., DeMicco, D. A., Breazna, A., & LaRosa, J. C. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.12.054 · Cited by 100
Nielsen, S., Schmitz, O., Møller, N., Pøksen, N., Klausen, I. C., Alberti, K. G. M. M., & Mogensen, C. E. (1993) · Diabetologia · doi:10.1007/bf02374502 · Cited by 100
Goicoechea, M., de Vinuesa, S. G., Lahera, V., Cachofeiro, V., Gómez-Campderá, F. J., Vega, A., Abad, S., & Luño, J. (2006) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006080938 · Cited by 98
A coronary primary prevention study of Scottish men aged 45?64 years: Trial design
(1992) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(92)90068-x · Cited by 98
Plasma lipoproteins and renal function during simvastatin treatment in diabetic nephropathy
Hommel, E. E., Andersen, P. H., Gall, M. ‐., Nielsen, F. S., Jensen, B., Rossing, P. R., Dyerberg, J., & Parving, H. ‐. (1992) · Diabetologia · doi:10.1007/bf02342442 · Cited by 97
Thomas, M. E., Harris, K. P. G., Ramaswamy, C., Hattersley, J., Wheeler, D. C., Varghese, Z., Williams, J. D., Walls, J., & Moorhead, J. F. (1993) · Kidney International · doi:10.1038/ki.1993.358 · Cited by 95
Penne, E. L., Blankestijn, P. J., Bots, M. L., van den Dorpel, M. A., Grooteman, M. P. C., Nubé, M. J., van der Tweel, I., ter Wee, P. M., & the CONTRAST study group (2005) · Current Controlled Trials in Cardiovascular Medicine · doi:10.1186/1468-6708-6-8 · Cited by 95
Effect of simvastatin on renal function in autosomal dominant polycystic kidney disease
van Dijk, M. A., Kamper, A. M., van Veen, S., Souverijn, J. H. M., & Blauw, G. J. (2001) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/16.11.2152 · Cited by 94
Thobari, J. A., Brantsma, A. H., Gansevoort, R. T., Visser, S. T., Asselbergs, F. W., van Gilst, W. H., de Jong, P. E., den Berg, L. T. W. D. J.-V., & on behalf of PREVEND study group (2006) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfl244 · Cited by 94
Impact of weight change on albuminuria in the general population
Bello, A. K., de Zeeuw, D., Nahas, M. E., Brantsma, A. H., Bakker, S. J. L., de Jong, P. E., & Gansevoort, R. T. (2007) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfm091 · Cited by 91
The cost-effectiveness of lipid lowering in patients with diabetes: results from the 4S trial
Jönsson, B., Cook, J. R., & Pedersen, T. R. (1999) · Diabetologia · doi:10.1007/s001250051441 · Cited by 88
Depression and cardiovascular morbidity and mortality: cause or consequence?
Stewart, R., North, F., West, T. M., SHARPLES, K. J., Simes, R. J., Colquhoun, D. M., White, H. D., & Tonkin, A. M. (2003) · European Heart Journal · doi:10.1016/j.ehj.2003.08.017 · Cited by 87
Pravastatin and cardiovascular risk in moderate chronic kidney disease
Nakamura, H., Mizuno, K., Ohashi, Y., Yoshida, T., Hirao, K., & Uchida, Y. (2009) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2009.03.031 · Cited by 87
Nakamura, T., Ushiyama, C., Hirokawa, K., Osada, S., Shimada, N., & Koide, H. (2001) · American Journal of Nephrology · doi:10.1159/000046648 · Cited by 86
Haffner, S. M. (1997) · Diabetes Care · doi:10.2337/diacare.20.4.469 · Cited by 85
Stewart, R., Sharples, K. J., North, F. M., Menkes, D. B., Baker, J., & Simes, J. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.20.3144 · Cited by 85
Nikolić, D., Banach, M., Nikfar, S., Salari, P., Mikhailidis, D. P., Toth, P. P., Abdollahi, M. R., Ray, K. K., Pencina, M. J., Małyszko, J., et al. (2013) · International Journal of Cardiology · doi:10.1016/j.ijcard.2013.08.060 · Cited by 84
Simes, R. J. (2002) · European Heart Journal · doi:10.1053/euhj.2001.2775 · Cited by 84
Lipid modulation in insulin-dependent diabetes mellitus
Fried, L. F., Forrest, K. Y. Z., Ellis, D., Chang, Y., Silvers, N., & Orchard, T. J. (2001) · Journal of Diabetes and its Complications · doi:10.1016/s1056-8727(01)00140-4 · Cited by 84
Soedamah‐Muthu, S. S. (2003) · Atherosclerosis · doi:10.1016/s0021-9150(02)00428-8 · Cited by 83
Design & Rationale of the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS)
Downs, J. R., Beere, P. A., Whitney, E. J., Clearfield, M. B., Weis, S. E., Rochen, J., Stein, E. A., Shapiro, D. R., Langendörfer, A., & Gotto, A. M. (1997) · The American Journal of Cardiology · doi:10.1016/s0002-9149(97)00347-0 · Cited by 82
Fellström, B., Zannad, F. M., Schmieder, R. E., Holdaas, H., Jardine, A. G., Rose, H., Wilpshaar, W., & the AURORA Study Group (2005) · Current Controlled Trials in Cardiovascular Medicine · doi:10.1186/1468-6708-6-9 · Cited by 81
Rahman, M., Baimbridge, C., Davis, B. R., Barzilay, J. I., Basile, J., Henriquez, M. A., Huml, A. M., Kopyt, N. P., Louis, G. T., Pressel, S., et al. (2008) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2008.05.027 · Cited by 81
Effect of fluvastatin on proteinuria in patients with immunoglobulin A nephropathy
Buemi, M. (2000) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2000.105330 · Cited by 78
Diercks, G. F. H., Janssen, W. M. T., Boven, A. J. V., Bak, A. A. A., de Jong, P. E., Crijns, H. J. G. M., & van Gilst, W. H. (2000) · The American Journal of Cardiology · doi:10.1016/s0002-9149(00)01042-0 · Cited by 77
Chonchol, M., Cook, T., Kjekshus, J., Pedersen, T. R., & Lindenfeld, J. (2007) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2006.11.043 · Cited by 76
Shepherd, J., Kastelein, J. J. P., Bittner, V., Carmena, R., DEEDWANIA, P. C., Breazna, A., Dobson, S., Wilson, D. J., Zuckerman, A. L., & WENGER, N. K. (2008) · Mayo Clinic Proceedings · doi:10.4065/83.8.870 · Cited by 75
Rahman, M. (2004) · Archives of Internal Medicine · doi:10.1001/archinte.164.9.969 · Cited by 75
Cost-effectiveness of statins for primary cardiovascular prevention in chronic kidney disease
Erickson, K. F., Japa, S., Owens, D. K., Chertow, G. M., Garber, A. M., & Goldhaber-Fiebert, J. D. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.12.034 · Cited by 74
Waters, D. D., LaRosa, J. C., Barter, P. J., Fruchart, J., Gotto, A. M., Carter, R., Breazna, A., Kastelein, J. J. P., & Grundy, S. M. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.07.041 · Cited by 74
Cerivastatin Improves Insulin Sensitivity and Insulin Secretion in Early-State Obese Type 2 Diabetes
Paniagua, J. A., López‐Miranda, J., Escribano, A., Berral, F. J., Marín, C., Bravo, D., Paz-Rojas, E., Gomez, P. J., Barcos, M., Moreno, J. A., et al. (2002) · Diabetes · doi:10.2337/diabetes.51.8.2596 · Cited by 74
(1993) · The American Journal of Cardiology · doi:10.1016/0002-9149(93)90438-i · Cited by 71
Effects of statins on inflammation in patients with acute and chronic coronary syndromes
Kinlay, S., & Selwyn, A. P. (2003) · The American Journal of Cardiology · doi:10.1016/s0002-9149(02)03268-x · Cited by 70
Fassett, R. G., Robertson, I. K., Ball, M. J., GERAGHTY, D. P., & Coombes, J. S. (2010) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2010.07.053 · Cited by 70
Nakamura, T. (2002) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/17.5.798 · Cited by 70
Dogra, G. K., Watts, G. F., Chan, D. C., & Stanton, K. (2005) · Diabetic Medicine · doi:10.1111/j.1464-5491.2004.01382.x · Cited by 69
Streja, L., Packard, C. J., Shepherd, J., Cobbe, S. M., & Ford, I. (2002) · The American Journal of Cardiology · doi:10.1016/s0002-9149(02)02599-7 · Cited by 66
Hague, W. E., Forder, P., Simes, J. R., Hunt, D., & Tonkin, A. M. (2003) · American Heart Journal · doi:10.1067/mhj.2003.1 · Cited by 65
Fassett, R. G., Robertson, I. K., Ball, M. J., GERAGHTY, D. P., Sharman, J. E., & Coombes, J. S. (2010) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.2683 · Cited by 64
Cited by
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz455 · Cited by 8,961
European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)
Authors/Task Force Members:, Perk, J., De Backer, G., Gohlke, H., Graham, I., Reiner, Ž., Verschuren, M., Albus, C., Benlian, P., Boysen, G., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs092 · Cited by 8,490
2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes
Knuuti, J., Wijns, W., Saraste, A., Capodanno, D., Barbato, E., Funck-Brentano, C., Prescott, E., Storey, R. F., Deaton, C., Cuisset, T., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz425 · Cited by 7,166
2016 European Guidelines on cardiovascular disease prevention in clinical practice
Piepoli, M. F., Hoes, A. W., Agewall, S., Albus, C., Brotons, C., Catapano, A. L., Cooney, M.-T., Corrà, U., Cosyns, B., Deaton, C., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw106 · Cited by 6,457
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.08.014 · Cited by 4,854
Metadata
- Authors
- Palmer, S. C., Navaneethan, S. D., Craig, J. C., Johnson, D. W., Perkovic, V., Hegbrant, J., & Strippoli, G. F.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2014-05-31
- Issue
- 5
- Pages
- CD007784-CD007784
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- OpenAlex
- W2134777998
- Cited by
- 331
- References
- 309
- FWCI
- 35.54
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.